- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05705635
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
January 27, 2023 updated by: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Multicenter, Randomized, Controlled Phase II Clinical Study of Comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in Second-line or Above Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
This trial is a multicenter, randomized, controlled clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
One hundred patients with locally advanced or metastatic gastric adenocarcinoma or gastric esophageal junction adenocarcinoma will be randomly assigned to the test group or the control group.
All patients will receive Docetaxel for injection (Albumin-bound) or Taxotere for treatment until disease progression.
Regular visits and imaging examinations will be conducted to compare the efficacy and safety of the two groups.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ruihua Xu
- Phone Number: +86-20-87343468
- Email: xurh@sysucc.org.cn
Study Locations
-
-
-
Guangzhou, China
- Recruiting
- Ethics Committee of Sun-Yat-Sen University Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: 18-75 (inclusive) (Whichever is on the day of signing the informed consent form).
- Willing to sign the informed consent form, willing and able to follow the program to accept visits, treatment and laboratory tests.
- Gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction confirmed by histology or cytology.
- Locally advanced or metastatic gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction after receiving at least first-line systematic treatment (defined as platinum/fluorouracil containing dual drug chemotherapy, with or without immunotherapy).
- Previous history with positive Her-2 expression requires anti-Her-2 medication; unknown Her-2 expression should define Her-2 status before enrollment.
- Adequate main organ function.
- Eastern Cooperative Oncology Group (ECOG) score 0-1.
- Expected lifetime≥ 3 months.
- Female patients of childbearing age must have a negative serum pregnancy test within 7 days prior to randomization; patients must agree to take adequate contraception from signing of ICF through 6 months after last dose, during which time women are not breastfeeding; male patients must agree to contraception and refuse sperm donation.
- At least one assessable lesion according to RECIST V1.1; The area should not have received radiotherapy in the past, or there is evidence that the lesion has made definite progress after radiotherapy.
Exclusion Criteria:
- Other active malignant tumors in the first 5 years of randomization.
- Uncontrolled serous cavity effusion requiring frequent drainage or medical intervention within 7 days before randomization.
- Patients with central nervous system metastasis.
- Patients whose previous medical history shows dMMR/MSI-H and who have not received immunotherapy in the past are not suitable for enrollment, and those whose dMMR/MSI status is unknown need to clarify the status before enrolment.
- Patients who have used paclitaxel/docetaxel in the past (except patients with disease progression more than one year after neoadjuvant/adjuvant treatment with paclitaxel/docetaxel).
- History of serious cardiovascular disease within 6 months before randomization.
- History of gastrointestinal perforation and/or fistula within 6 months before randomization.
- Hypertension with poor control during the screening period.
- Patients with active hepatitis B, hepatitis C or HIV.
- Patients with severe chronic or active infections that require systemic antimicrobial, antifungal, or antiviral therapy.
- Patients with gastrointestinal obstruction and active inflammatory bowel disease within 28 days before randomization.
- Toxic reaction caused by any previous treatment has not recovered to level 1 or below (CTCAE5.0).
- Major organ surgery (except puncture biopsy) within 28 days before randomization.
- Have received chemotherapy, radiotherapy, targeted therapy, immunotherapy or other anti-tumor treatment of clinical research drugs within 28 days before randomization.
- Have received traditional Chinese medicine with anti-tumor indications within 14 days before randomization.
- Have received powerful CYP3A4 inhibitor or inducer within 14 days before randomization.
- Allergic to and / or contraindication to albumin or docetaxel.
- Known allergy and/or contraindication to glucocorticoids.
- Patients with psychiatric neurological disorders that may affect trial adherence, or patients with a history of drug dependence / alcohol dependence.
- Other situations that the researcher thinks are not suitable for participating in this study.
- Patients participated in another clinical study at the same time, unless it is an observational (non intervention) clinical study or is in the follow-up period of an intervention study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Docetaxel for Injection (Albumin-bound)
Docetaxel for Injection (Albumin-bound) will be administrated by intravenous infusion once every 3 weeks.
|
Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
|
ACTIVE_COMPARATOR: Taxotere
Taxotere will be administrated by intravenous infusion once every 3 weeks.
|
Taxotere, by intravenous infusion, every 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free-Survival (PFS)
Time Frame: Up to approximately 2 years
|
The duration is from the randomized time to disease progression or death due to any reason.
|
Up to approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of AE and SAE
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Overall response rate (ORR)
Time Frame: Up to approximately 2 years
|
The primary endpoint is objective response rate,which equals CR+PR.
|
Up to approximately 2 years
|
Disease control rate (DCR)
Time Frame: Up to approximately 2 years
|
The primary endpoint is Disease Control rate,which equals CR+PR+SD.
|
Up to approximately 2 years
|
Duration of Response (DoR)
Time Frame: Up to approximately 2 years
|
The time from the first assessment of tumor as CR or PR to the first assessment as PD or death from any cause
|
Up to approximately 2 years
|
Overall survival (OS)
Time Frame: Up to approximately 2 years
|
OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 12 weeks till death or lost
|
Up to approximately 2 years
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentration of docetaxel (free and total)
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
At the end of Cycle 1(each cycle is 21 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Ruihua Xu, Sun Yat-sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 13, 2023
Primary Completion (ANTICIPATED)
May 1, 2023
Study Completion (ANTICIPATED)
December 1, 2024
Study Registration Dates
First Submitted
November 22, 2022
First Submitted That Met QC Criteria
January 27, 2023
First Posted (ACTUAL)
January 31, 2023
Study Record Updates
Last Update Posted (ACTUAL)
January 31, 2023
Last Update Submitted That Met QC Criteria
January 27, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HB1801-007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingMetastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Gastric Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Diffuse Gastric Adenocarcinoma | Gastric Intestinal Type Adenocarcinoma | Gastric Mixed AdenocarcinomaUnited States, Canada
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
University of ChicagoNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IIB Gastric Cancer | Stage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal AdenocarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States, Puerto Rico
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingGastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Ukrainian Society of Clinical OncologyRecruitingStomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma | Advanced Gastroesophageal Junction AdenocarcinomaUkraine
-
M.D. Anderson Cancer CenterRecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
Clinical Trials on Docetaxel for injection (Albumin-bound)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingPancreatic CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruiting
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruitingAdvanced Solid TumorsChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingLocally Advanced Unresectable Esophageal Squamous CarcinomaChina
-
China Medical University, ChinaRecruiting
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.UnknownNon-Small Cell Lung CancerChina
-
Sun Yat-sen UniversityShanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.RecruitingEsophageal Small Cell CarcinomaChina
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdNot yet recruiting
-
Peking UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingGastric Cancer | Adenocarcinoma of Esophagogastric JunctionChina
-
Fuzhou General HospitalUnknownNasopharyngeal CarcinomaChina